Overcoming Resistance & Exploring Treatment Strategies in MDS/AML

Time: 9:30 am
day: Conference Day One


• Identifying the specific challenges associated with modelling MDS and their impact on translatability to the clinic

• Presenting findings from NRASD12/BCL-2 mouse models of HR-MDS/AML demonstrating the ability to overcome resistance to Venetoclax, a BCL-2 inhibitor, by utilizing a Mek inhibitor

• Presenting recent findings from the newly established RAS/p53R172H model of AML, highlighting ongoing investigations and preliminary results